Chemotherapy for ovarian cancer: Current concepts

Seminars in Surgical Oncology

Volumn 17, Issue 3, 1999, Pages 181-188

  Herrin, Vincent E ^a   Thigpen, J Tate ^a,b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Alkylating antineoplastic agents; Carboplati n; Cisplatin; Combined antineoplastic agents; Combined modality therapy; Cyclophosphamide; Disease free survival; Doxorubicin; Drug administration schedule; Drug dose response relationship; Hematopoietic stem cell transplantation; Neoplasm staging; Neoplasms drug therapy; Ovarian neoplasms surgery mortality pathology drug therapy; Paclitaxel; Phase III clinical trial; Phytogenic antineoplastic agents; Platinum; Survival rate; Tamoxifen; Topotecan

Indexed keywords

ALKYLATING AGENT; ANTIHISTAMINIC AGENT; CARBOPLATIN; CISPLATIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL; PLATINUM COMPLEX; STEROID; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN;

AUTOTRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CONTINUOUS INFUSION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE; GYNECOLOGIC CANCER; HEART ARRHYTHMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PLATINUM COMPOUNDS; SALVAGE THERAPY;

EID: 0032867917     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199910/11)17:3<181::AID-SSU7>3.0.CO;2-7     Document Type: Review

References (54)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA: Cancer J Clin 1999;49:8-31.
2. th ed. New York: Lippincott-Raven; 1997. p. 1502-1539.
3. International Federation of Gynecology and Obstetrics Cancer Committee. Staging announcement. Gynecol Oncol 1986;25:383-385.
4. International Federation of Gynecology and Obstetrics. Changes in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987;156:236.
5. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. NCI Monogr 1975;42:101-104.
6. van der Burg ME, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629-634.
7. Hoskins WJ: Surgical staging and cytoreductive surgery of epithelial ovarian cancer [Review]. Cancer 1993;71(4 Suppl):1534-1540.
8. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-166.
9. Hoskins WJ, McGuire WP, Brady MF, et al: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian cancer. Am J Obstet Gynecol 1994;170:974-980.
10. Omura GA, Bundy BN, Berek JS, et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989;7:457-465.
11. Allen DG, Heintz AP, Touw FW: A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1995;16:349-356.
12. Decker DG, Fleming TR, Malkasian GD Jr, et al: Cyclophosphamide plus cis-platinum in combination: treatment program for stage III or IV ovarian carcinoma. Obstet Gynecol 1982;60:481-487.
13. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al: Randomized trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2(8403):594-600.
14. Williams CJ, Mead GM, Macbeth FR, et al: Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol 1985;3:1455-1462.
15. Omura G, Blessing JA, Ehrlich CE, et al: A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian cancer. A Gynecologic Oncology Group Study. Cancer 1986;57:1725-1730.
16. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. BMJ 1991;303(6807):884-893.
17. McGuire WP: Primary treatment of epithelial ovarian malignancies. Cancer 1993;71:1541-1550.
18. Balvert-Locht HR, Coebergh JW, Hop WC, et al: Improved prognosis of ovarian cancer in The Netherlands during the period 1975-1985: a registry-based study. Gynecol Oncol 1991;42:3-8.
19. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 1987;5:756-767.
20. Taylor AE, Wiltshaw E, Gore ME, et al: Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 1994;12:2066-2070.
21. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer [published erratum appears in J Clin Oncol 1992;10:1505]. J Clin Oncol 1992;10:706-717.
22. Swenerton K, Jeffrey J, Stuart G, et al: Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials group. J Clin Oncol 1992;10:718-726.
23. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of taxol and cisplatin: a phase 1 and pharmacologic study. J Clin Oncol 1991;9:1692-1703.
24. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989;111:273-279.
25. Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 1992;10:1748-1753.
26. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-1753.
27. Kohn EC, Sarosy G, Bicher A, et al: Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 1994;86:18-24.
28. Rowinsky EK, Mackey MK, and Goodman SN: Meta-analysis of paclitaxel dose-response and dose-intensity in recurrent or refractory ovarian cancer [Abstract]. Proc Am Soc Clin Oncol 1996; 15:284.
29. Omura GA, Brady MF, Delmore JE, et al: A randomized trial of paclitaxel (t) at 2 dose levels and filgrastim (g; G-CSF) at 2 doses in platinum (p) pretreated epithelial ovarian cancer (ovca): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG study [Abstract]. Proc Am Soc Clin Oncol 1996;15:280.
30. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
31. Piccart MJ, Bertelsen K, Stuart G, et al: Is cisplatin-paclitaxel the standard in first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience [Abstract]. Proc Am Soc Clin Oncol 1997;16:352a.
32. Stuart G, Bertelsen K, Mangioni C, et al: Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVS, NCI-C CTG and Scottish intergroup trial [Abstract]. Proc Am Soc Clin Oncol 1998;17:361a.
33. Muggia FM, Braly PS, Brady MF, et al: Phase III trial of cisplatin or paclitaxel versus their combination in suboptimal stage III and IV epithelial ovarian cancer: Gynecologic Oncology Group study #132 [Abstract]. Proc Am Soc Clin Oncol 1997;16:352a.
34. rd International Collaborative Ovarian Neoplasm study (ICON3) [Abstract]. Proc Am Soc Clin Oncol 1999; 18:356a.
35. Young RC, Walton LA, Ellenberg SS, et al: Adjuvant therapy in stage I and II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 1990;322:1021-1027.
36. Colombo N, Chiari S, Maggioni A, et al: Controversial issues in the management of early epithelial ovarian cancer: conservative surgery and role of adjuvant therapy [Review]. Gynecol Oncol 1994;55(3 Pt 2):S47-S51.
37. Neijt JP, Hansen M, Hansen SW, et al: Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin [Abstract]. Proc Am Soc Clin Oncol 1997;16:352a.
38. duBois A, Lueck HJ, Meier W, et al: Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial [Abstract]. Proc Am Soc Clin Oncol 1999;18:356a.
39. Ozols RF, Bundy BN, Fowler J, et al: Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer: a Gynecologic Oncology Group trial (GOG 158) [Abstract]. Proc Am Soc Clin Oncol 1999;18:356a.
40. Hakes TB, Hoskins WJ, Jones WB, et al: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin and cisplatin (CAP) in stage III and IV ovarian cancer [Abstract]. Proc Am Soc Clin Oncol 1990;9:156.
41. Bertelsen K, Jakobsen A, Stroyer J, et al: A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 1993;49:30-36.
42. Markman M, Rose P, Kennedy A, et al: A phase II study of 96 hour paclitaxel (p) as salvage therapy in ovarian carcinoma (oc) [Abstract]. Proc Am Soc Clin Oncol 1996;15:283.
43. Rose PG, Blessing JA, Mayer AR, Homesley HD: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998;16:405-410.
44. ten Bokkel Huinink W, Gore M, Carmichael J, et al: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193.
45. Muggia FM, Hainsworth JD, Jeffers S, et al: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997;15:987-993.
46. Shapiro JD, Millward MJ, Rischin D, et al: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol 1996;63:89-93.
47. Lund B, Hansen OP, Theilade K, et al: Phase II study of gemcitabine (2′, 2′- difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994;86:1530-1533.
48. Bajetta E, Di Leo A, Biganzoli L, et al: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996;14:2546-2551.
49. Markman M, Hakes T, Reichman B, et al: Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1992;10:243-248.
50. Markman M, Iseminger KA, Hatch KD, et al: Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 1996;62:4-6.
51. Alberts DS, Liu PY, Hannigan EV, et al: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955.
52. Markman M, Bundy B, Benda J, et al: Randomized phase III study of intravenous cisplatin/paclitaxel versus moderately high-dose IV carboplatin followed by IV paclitaxel and intraperitoneal cisplatin in optimal residual cancer: an intergroup trial (GOG, SWOG, ECOG) [Abstract]. Proc Am Soc Clin Oncol 1998;17:361a.
53. Herrin VE, Thigpen JT: High-dose chemotherapy in ovarian carcinoma [Review]. Semin Oncol 1999;26:99-105.
54. Horowitz MM, Stiff PJ, Veum-Stone J, et al: Outcome of autotransplants for advanced ovarian cancer [Abstract]. Proc Am Soc Clin Oncol 1997;16:353a.